Organisation

SWElife´s work is conducted by a limited staff and a governing board and an advisory board, along with a number of specialised committees, projects and working groups. We are a national organisation with professionals from a wide range of organisations, representing all life science sectors and regions in Sweden.

Programme office

Peter Nordström, Programme Director, SWElife
Thomas Gunnarsson, Project leader, Lund University
Karin Agerman, Project leader, Uppsala BIO
Sofia Waldemarson, Project leader, Lund University
Sara Bernstrup Nilsson, Communicator, SWElife
Michael De Roy, Administration and Economy, Lund University

Governing Board

Martin Ingvar, chairman, Karolinska Institutet
Christina Östberg Lloyd, vice-chairman, Novo Nordisk
Thomas Anderzon, GE Healthcare
Maria Anvret, University of Gothenburg
Carl Borrebaeck, Lund University
Beritte Christensson, AstraZeneca
Erik Forsberg, Uppsala BIO
Rita Jedlert, Region Skåne
Beatrice Melin, Umeå University/RCC Norr
Örjan Norberg, Västerbottens läns landsting
Erik Renström, LUDC, Lund University
Eva Sjökvist Saers, APL, Apotek Produktion & Laboratorier AB
Kaj Stenlöf, Vetenskapsrådet

Advisory Board

Hans Enocson, Chairman, GE
Elisabeth Björk, AstraZeneca
Peter Egardt, Länsstyrelsen Uppsala
Bo Ahrén, Lund University
Chris Heister, Länsstyrelsen Stockholm
Ann-Sofi Lodin, Västra Götalandsregionen
Karl-Eric Magnusson, Linköping University, Umeå University
Lars Börjesson, Chalmers
Anders Sylvan, Västerbottens Läns Landsting

Arena

Working group

Thomas Gunnarsson, project leader, Lund University, LUDC
Helena Ljusberg, Lund University
Peter Sartipy, AstraZeneca
Mikael Rydén, Karolinska Institutet

Advisory group

Maria Anvret, University of Gothenburg
Erik Renström, LUDC, Lund University
Helena Ljusberg, Lund University

C3 – Competences, Capabilities and Capital

Working group

Karin Agerman, project leader, Uppsala BIO
Helén Fält, Umeå Biotech Incubator (UBI)
Göran Leonardsson, Sahlgrenska Science Park
Ulrika Andreasson, Lund University (on leave)
Sofia Waldemarson, Lund University

Advisory group

Örjan Norberg, Västerbottens Läns Landsting
Erik Forsberg, Uppsala BIO
Bo-Ragnar Tolf, Karolinska Institutet Innovation Office
Stanko Skrtic, AstraZeneca
Magnus Björsne, AstraZeneca
Mats Berggren, Merck

CIT – Clinical Innovation and Transformation

Working group

Sofia Waldemarson, project leader, Lund University
Mats Berggren, Merck/LIF
Björn Arvidsson, Roche Pharma/LIF
Carsten Rose, Lund University
Bengt Westermark, Uppsala University
Tobias Sjöblom Uppsala University, U-CAN

 

 

 

 

Specific Initiatives

Clinical Informatics

Björn Arvidsson, workstream leader, Roche Pharma/LIF
Per Byström, Novartis
Tobias Sjöblom Uppsala University, U-CAN
Mathias Saverstam Pfizer
Malin Nordström, Karolinska Universitetssjukhuset

Predictive biomarker testing (developed and implemented)

Mats Berggren, workstream leader, Merck/LIF
Johanna Asklin, Lund University
Mef Nilbert RCC
Jacob Ehnfors, Roche Diagnostics/LIF
Laura Chirica, Immunovia
Astrid Torstensson, AstraZeneca
Anna Martling, Karolinska Institutet
Anna Levander, ThermoFisher

Increased competence and strengthening of clinical research units – oncology/hematology

Carsten Rose, workstream leader, Lund University
Eva Eliasson, Pfizer/LIF
Ulrika Brunell Abrahamsson, BMS/LIF
Jan Degerfält, Flexibel utbildning-onkologi
Dan Grandér, Cancer Centrum Karolinska
Marie Eklund, Läkemedelsakademin/Apotekarsocieteten
Nils Wilking, Skånes Onkologiska Klinik
Joachim Gullbo, Karolinska Institutet
Mef Nilbert, RCC Syd
Harald Andersson, Lund University
Cecilia Grafman, Skånes Onkologiska Klinik

Facilitating of triple (hexa) helix

Bengt Westermark, workstream leader, Uppsala University
Lars Holmberg, RCC Uppsala-Örebro, with support from Sonja Eaker-Fält, Nationella biobanksrådet
Tobias Sjöblom, Uppsala University, U-CAN
Elin Fernholm, Pfizer
Maria Planck, Lund University
Rune Toftgård, KI StratCan
Bengt Gustavsson, Celgene/LIF

Creation of nation-wide patient cohorts

Tobias Sjöblom, workstream leader, Uppsala University, U-CAN
Sonja Eaker-Fält, Nationella biobanksrådet
Anna Beskow, Uppsala biobank
Linda Paulson, Sahlgrenska biobank
Lena Brynne, Stockholms medicinska biobank
Christer Larsson, RCC Syd
Maréne Landström, Patologi, Umeå University
Martin Malmberg, Onkologi, Lund University
Pär Stattin, Urologi, Umeå University
Tony Hansson, Uppsala University, U-CAN
Elin Fernholm, Pfizer
Björn Arvidsson, Roche Pharma/LIF

Public-private venture capital

Lars H Bruzelius, work stream leader, LU Bio
Jonas Gallon, Innovator Skåne

CCE (Centers of Clinical Excellence)

Maria Anvret, University of Gothenburg
Catharina Bäärnhielm, Karolinska Institutet
Catharina Östberg, Pfizer

Digital Health (3Helix–3R)

Patrik Georgii Hemming, Karolinska University Hospital